Global Structural Heart Device Market to Reach USD 32.6B by 2031: HDIN Research
Date : 2026-11-13
Reading : 320
HDIN Research's latest executive intelligence report reveals that the global structural heart device market is projected to enter 2026 valued between USD 17.1 billion and USD 18.1 billion. Expanding at a compound annual growth rate (CAGR) of 8.5% to 12.5%, aggregate industry revenue is modeled to reach between USD 25.7 billion and USD 32.6 billion by 2031.
Proprietary supply-side modeling confirms that while Transcatheter Aortic Valve Replacement (TAVR) retains absolute revenue primacy, structural heart intervention is experiencing a decisive clinical migration. Value creation is tilting toward Transcatheter Mitral and Tricuspid Therapies (TMTT), bioresorbable occlusion architectures, and specialized mechanical circulatory support platforms designed to intercept heart failure in an aging global population exceeding 64 million clinical cases.
Strategic Moats & Headwinds: The Post-Aortic Transition
The structural heart landscape is navigating an operational pivot characterized by elevated clinical hurdles, margin realignment, and high R&D intensity.
Indication Expansion and Calcification Frontiers
TAVR growth is breaking past its historical boundaries in high- and intermediate-risk senile aortic stenosis. Robust data from the landmark EARLY TAVR trial has shifted clinical consensus toward intervening in asymptomatic severe aortic stenosis, converting watch-and-wait cohorts into immediate procedural candidates. Simultaneously, novel anchoring geometries—exemplified by JenaValve’s Trilogy platform (partnered with Peijia Medical as TaurusTrio)—are establishing therapeutic access in pure, non-calcified aortic regurgitation, a substantial demographic previously untreatable via standard transcatheter techniques.
Material Science: The Bioabsorbable and Dry-Tissue Paradigm Shift
Standard permanent metallic implants face substitution risks:
* Occlusion Matrices: In septal repair, nitinol-wire frames are yielding share to fully bioresorbable polymer matrices. Lepu ScienTech’s MemoSorb Atrial Septal Defect (ASD) and Patent Foramen Ovale (PFO) portfolios demonstrate rapid absorption post-endothelialization, eliminating lifelong foreign-body stress and facilitating repeat transseptal puncture access.
* Bioprosthetic Preservation: In tissue valves, the obsolescence of glutaraldehyde preservation is accelerating. Edwards Lifesciences’ RESILIA platform (utilizing glycerol capping to enable dry-valve storage) and Anteris Technologies’ single-piece ADAPT tissue (cleared for the randomized global PARADIGM trial under an FDA IDE) demonstrate superior resistance to structural valve deterioration, targeting implant durability milestones beyond 15 to 20 years.
Upstream Constraints and Capex Rationalization
Our field audit indicates escalating barriers to scale. Upstream tissue supply chains require disease-free bovine pericardial sourcing with strict BSE-clearance protocols, alongside cleanroom micro-suturing processes that cannot be easily automated. At the enterprise level, portfolio rationalization has intensified. Boston Scientific’s global discontinuation of its ACURATE TAVR platform, resulting in an USD 87 million restructuring charge, highlights that tier-one players will dismantle non-differentiated pipelines to concentrate capital on scalable, first-in-class assets.
Sub-Segment Architecture: TMTT and Cardioembolic Occlusion
Transcatheter Mitral & Tricuspid Therapies (TMTT)
Epidemiological models indicate the global population suffering from mitral and tricuspid regurgitation is several times larger than that with calcific aortic stenosis. While Abbott’s MitraClip and Edwards’ PASCAL systems dominate Transcatheter Edge-to-Edge Repair (TEER), regulatory approvals for transcatheter tricuspid replacement—led by Edwards' EVOQUE and Jenscare’s LuX-Valve Plus—represent the fastest-growing procedural sector. In transcatheter mitral valve replacement (TMVR), platforms including Abbott’s Tendyne, HighLife (which achieved CE Mark in January 2026), and Sino Medical’s AccuFit are systematically addressing high surgical-risk patient segments.
Cardioembolic Prevention (LAAO & PFO)
Stroke reduction protocols are driving structural occlusion volumes. With over 30% of ischemic strokes in non-valvular atrial fibrillation originating in the left atrial appendage, Boston Scientific’s WATCHMAN FLX Pro and Abbott’s Amplatzer Amulet continue their international expansion. Concurrently, regional players are scaling rapidly: MicroPort Scientific’s AnchorMan LAAO system logged approximately 1,000 commercial implants in 2025 (+360% YoY) and earned CE Mark approval, signaling domestic Asian readiness to compete in mature Western regulatory hubs.
Regional Granularity: Divergent Regulatory & Pricing Paradigms
North America
Retaining greater than 50% of aggregate global value, the United States remains the commercial profit center for structural heart medtech. Favorable reimbursement rates for complex catheter procedures and high capital investment in hybrid operating suites support strong average selling prices (ASPs). Premarket Approval (PMA) pathways remain rigorous; recent entries include Medtronic’s Evolut FX+ platform and EBR Systems' WiSE CRT System, which secured commercial integration across initial US hospital networks.
Europe
Accounting for more than 33% of global value, Europe faces structural operational friction. Compliance mandates under EU Medical Device Regulation (EU MDR 2017/745) continue to prolong clinical review cycles, forcing mid-sized vendors to rationalize non-core product portfolios. However, financial operating risk in the region saw relief following parliamentary actions in Italy that capped historical medical device payback liabilities (2015–2018) at approximately 25% of original claims, allowing Medtronic, Teleflex, and Artivion to release litigation reserves.
Asia-Pacific and Emerging Geographies
Asia-Pacific represents the largest growth engine for procedural volume:
* China: The National Healthcare Security Administration (NHSA) expanded Volume-Based Procurement (VBP) across metallic septal occluders and catheter access tools. While standard metal devices experienced planned price compression, the shift has accelerated physician migration to premium non-VBP alternatives: domestic sales volumes of Lepu ScienTech’s MemoSorb bioabsorbable occluders surged over 30% YoY in 2025. Concurrently, the NMPA Innovation Green Channel is expediting market entry, granting Peijia Medical seven expedited approvals across structural platforms.
* India, Latin America, and GCC: India's Meril Life Sciences is expanding global market reach with its Myval and Myval Octacor balloon-expandable TAVR series. Latin American growth centers on private cardiac centers in Brazil and Mexico, while the Middle East is anchored by sovereign healthcare investments across the Gulf Cooperation Council (GCC) to establish specialized cardiovascular centers of excellence.
Analyst Insight: The HDIN Viewpoint
"Institutional market participants are committing a category error by assuming Transcatheter Mitral and Tricuspid Therapies will trace the rapid commercial adoption curves observed during the early growth of TAVR," states the Lead Medical Technology Analyst at HDIN Research.
"Our field assessments reveal that while the target anatomical disease pools for mitral and tricuspid regurgitation are epidemiologically larger than aortic stenosis, the operational barrier to treatment is an order of magnitude more demanding. Complex transcatheter repairs and replacements demand sophisticated intra-procedural 3D transesophageal echocardiography (TEE), intracardiac echocardiography (ICE), and lengthy physician proctoring curves. Consequently, procedure volumes through 2028 will concentrate almost exclusively within high-volume tertiary centers of excellence. Medtech vendors lacking comprehensive, direct-to-physician clinical proctoring networks and consignment logistics will face plateauing clinical adoption rates, regardless of their implant’s theoretical hydrodynamic performance."
Enterprise Consolidation and Pipeline Dynamics
Corporate transaction volume reflects an urgent push to command integrated interventional suites. Boston Scientific’s definitive agreement in January 2026 to acquire Penumbra at USD 374 per share (an enterprise valuation of approximately USD 14.5 billion) underscores the strategic priority for diversified market leaders to pair structural heart access devices with interventional thrombectomy and vascular portfolios.
Concurrently, mid-tier and Asian innovators are deploying corporate spin-offs to insulate long-gestation, high-risk R&D assets. Peijia Medical’s structural spin-off of its Frontier Technology unit—advancing its MonarQ TTVR valve, shockwave calcification remodeling systems, and ReachTact robotic catheter delivery—exemplifies a trend where established device developers utilize targeted venture structures to de-risk platform innovation without penalizing core operational margins.
Sample Pages Download
Click the PDF download link under 'Related Topics' to access the sample pages of this comprehensive report: Global Structural Heart Device Market Insights 2026.
About HDIN Research
HDIN Research focuses on providing market consulting services. As an independent third-party consulting firm, it is committed to providing in-depth market research and analysis reports to institutional investors, corporate strategists, and medtech executives worldwide.
* Website: www.hdinresearch.com
* Inquiries: sales@hdinresearch.com
*AI Transparency Disclosure: This market intelligence was curated by HDIN Research analysts with technical drafting assistance from AI. All data, logic, and strategic conclusions have been audited and verified by our human editorial board to ensure professional-grade accuracy.*
Proprietary supply-side modeling confirms that while Transcatheter Aortic Valve Replacement (TAVR) retains absolute revenue primacy, structural heart intervention is experiencing a decisive clinical migration. Value creation is tilting toward Transcatheter Mitral and Tricuspid Therapies (TMTT), bioresorbable occlusion architectures, and specialized mechanical circulatory support platforms designed to intercept heart failure in an aging global population exceeding 64 million clinical cases.
Strategic Moats & Headwinds: The Post-Aortic Transition
The structural heart landscape is navigating an operational pivot characterized by elevated clinical hurdles, margin realignment, and high R&D intensity.
Indication Expansion and Calcification Frontiers
TAVR growth is breaking past its historical boundaries in high- and intermediate-risk senile aortic stenosis. Robust data from the landmark EARLY TAVR trial has shifted clinical consensus toward intervening in asymptomatic severe aortic stenosis, converting watch-and-wait cohorts into immediate procedural candidates. Simultaneously, novel anchoring geometries—exemplified by JenaValve’s Trilogy platform (partnered with Peijia Medical as TaurusTrio)—are establishing therapeutic access in pure, non-calcified aortic regurgitation, a substantial demographic previously untreatable via standard transcatheter techniques.
Material Science: The Bioabsorbable and Dry-Tissue Paradigm Shift
Standard permanent metallic implants face substitution risks:
* Occlusion Matrices: In septal repair, nitinol-wire frames are yielding share to fully bioresorbable polymer matrices. Lepu ScienTech’s MemoSorb Atrial Septal Defect (ASD) and Patent Foramen Ovale (PFO) portfolios demonstrate rapid absorption post-endothelialization, eliminating lifelong foreign-body stress and facilitating repeat transseptal puncture access.
* Bioprosthetic Preservation: In tissue valves, the obsolescence of glutaraldehyde preservation is accelerating. Edwards Lifesciences’ RESILIA platform (utilizing glycerol capping to enable dry-valve storage) and Anteris Technologies’ single-piece ADAPT tissue (cleared for the randomized global PARADIGM trial under an FDA IDE) demonstrate superior resistance to structural valve deterioration, targeting implant durability milestones beyond 15 to 20 years.
Upstream Constraints and Capex Rationalization
Our field audit indicates escalating barriers to scale. Upstream tissue supply chains require disease-free bovine pericardial sourcing with strict BSE-clearance protocols, alongside cleanroom micro-suturing processes that cannot be easily automated. At the enterprise level, portfolio rationalization has intensified. Boston Scientific’s global discontinuation of its ACURATE TAVR platform, resulting in an USD 87 million restructuring charge, highlights that tier-one players will dismantle non-differentiated pipelines to concentrate capital on scalable, first-in-class assets.
Sub-Segment Architecture: TMTT and Cardioembolic Occlusion
Transcatheter Mitral & Tricuspid Therapies (TMTT)
Epidemiological models indicate the global population suffering from mitral and tricuspid regurgitation is several times larger than that with calcific aortic stenosis. While Abbott’s MitraClip and Edwards’ PASCAL systems dominate Transcatheter Edge-to-Edge Repair (TEER), regulatory approvals for transcatheter tricuspid replacement—led by Edwards' EVOQUE and Jenscare’s LuX-Valve Plus—represent the fastest-growing procedural sector. In transcatheter mitral valve replacement (TMVR), platforms including Abbott’s Tendyne, HighLife (which achieved CE Mark in January 2026), and Sino Medical’s AccuFit are systematically addressing high surgical-risk patient segments.
Cardioembolic Prevention (LAAO & PFO)
Stroke reduction protocols are driving structural occlusion volumes. With over 30% of ischemic strokes in non-valvular atrial fibrillation originating in the left atrial appendage, Boston Scientific’s WATCHMAN FLX Pro and Abbott’s Amplatzer Amulet continue their international expansion. Concurrently, regional players are scaling rapidly: MicroPort Scientific’s AnchorMan LAAO system logged approximately 1,000 commercial implants in 2025 (+360% YoY) and earned CE Mark approval, signaling domestic Asian readiness to compete in mature Western regulatory hubs.
Regional Granularity: Divergent Regulatory & Pricing Paradigms
North America
Retaining greater than 50% of aggregate global value, the United States remains the commercial profit center for structural heart medtech. Favorable reimbursement rates for complex catheter procedures and high capital investment in hybrid operating suites support strong average selling prices (ASPs). Premarket Approval (PMA) pathways remain rigorous; recent entries include Medtronic’s Evolut FX+ platform and EBR Systems' WiSE CRT System, which secured commercial integration across initial US hospital networks.
Europe
Accounting for more than 33% of global value, Europe faces structural operational friction. Compliance mandates under EU Medical Device Regulation (EU MDR 2017/745) continue to prolong clinical review cycles, forcing mid-sized vendors to rationalize non-core product portfolios. However, financial operating risk in the region saw relief following parliamentary actions in Italy that capped historical medical device payback liabilities (2015–2018) at approximately 25% of original claims, allowing Medtronic, Teleflex, and Artivion to release litigation reserves.
Asia-Pacific and Emerging Geographies
Asia-Pacific represents the largest growth engine for procedural volume:
* China: The National Healthcare Security Administration (NHSA) expanded Volume-Based Procurement (VBP) across metallic septal occluders and catheter access tools. While standard metal devices experienced planned price compression, the shift has accelerated physician migration to premium non-VBP alternatives: domestic sales volumes of Lepu ScienTech’s MemoSorb bioabsorbable occluders surged over 30% YoY in 2025. Concurrently, the NMPA Innovation Green Channel is expediting market entry, granting Peijia Medical seven expedited approvals across structural platforms.
* India, Latin America, and GCC: India's Meril Life Sciences is expanding global market reach with its Myval and Myval Octacor balloon-expandable TAVR series. Latin American growth centers on private cardiac centers in Brazil and Mexico, while the Middle East is anchored by sovereign healthcare investments across the Gulf Cooperation Council (GCC) to establish specialized cardiovascular centers of excellence.
Analyst Insight: The HDIN Viewpoint
"Institutional market participants are committing a category error by assuming Transcatheter Mitral and Tricuspid Therapies will trace the rapid commercial adoption curves observed during the early growth of TAVR," states the Lead Medical Technology Analyst at HDIN Research.
"Our field assessments reveal that while the target anatomical disease pools for mitral and tricuspid regurgitation are epidemiologically larger than aortic stenosis, the operational barrier to treatment is an order of magnitude more demanding. Complex transcatheter repairs and replacements demand sophisticated intra-procedural 3D transesophageal echocardiography (TEE), intracardiac echocardiography (ICE), and lengthy physician proctoring curves. Consequently, procedure volumes through 2028 will concentrate almost exclusively within high-volume tertiary centers of excellence. Medtech vendors lacking comprehensive, direct-to-physician clinical proctoring networks and consignment logistics will face plateauing clinical adoption rates, regardless of their implant’s theoretical hydrodynamic performance."
Enterprise Consolidation and Pipeline Dynamics
Corporate transaction volume reflects an urgent push to command integrated interventional suites. Boston Scientific’s definitive agreement in January 2026 to acquire Penumbra at USD 374 per share (an enterprise valuation of approximately USD 14.5 billion) underscores the strategic priority for diversified market leaders to pair structural heart access devices with interventional thrombectomy and vascular portfolios.
Concurrently, mid-tier and Asian innovators are deploying corporate spin-offs to insulate long-gestation, high-risk R&D assets. Peijia Medical’s structural spin-off of its Frontier Technology unit—advancing its MonarQ TTVR valve, shockwave calcification remodeling systems, and ReachTact robotic catheter delivery—exemplifies a trend where established device developers utilize targeted venture structures to de-risk platform innovation without penalizing core operational margins.
Sample Pages Download
Click the PDF download link under 'Related Topics' to access the sample pages of this comprehensive report: Global Structural Heart Device Market Insights 2026.
About HDIN Research
HDIN Research focuses on providing market consulting services. As an independent third-party consulting firm, it is committed to providing in-depth market research and analysis reports to institutional investors, corporate strategists, and medtech executives worldwide.
* Website: www.hdinresearch.com
* Inquiries: sales@hdinresearch.com
*AI Transparency Disclosure: This market intelligence was curated by HDIN Research analysts with technical drafting assistance from AI. All data, logic, and strategic conclusions have been audited and verified by our human editorial board to ensure professional-grade accuracy.*